心脏MRI与FDG PET在心脏结节病中的预后价值:系统综述与荟萃分析
左室和右室晚期钆增强及FDG摄取均与MACE相关,但直接比较研究显示仅LGE的预测价值独立显著,FDG摄取未达统计学意义。
要点
- 左室LGE预测MACE的OR为8.0,右室LGE OR为13.1,均显著。
- FDG摄取预测MACE的OR为2.1,直接比较研究中不显著。
- 报告心脏结节病时需关注左室及右室LGE的存在与范围。
关键影像表现/征象
- 心脏MRI显示左室晚期钆增强(LGE)与MACE显著相关(OR 8.0,95%CI 4.3-15.0,P<.001)。
- 右室LGE也与MACE显著相关(OR 13.1,95%CI 5.2-33,P<.001)。
- FDG PET显示FDG摄取与MACE相关(OR 2.1,95%CI 1.4-3.2,P<.001),右室FDG摄取OR 4.1(95%CI 1.9-8.9,P<.001)。
- 在直接比较研究中,LGE预测MACE的OR为10.4(95%CI 3.5-30.5,P<.001),而FDG摄取OR 1.9(95%CI 0.82-4.4,P=.13)未达统计学意义。
- 荟萃回归显示结果因检查方式而异(P=.006)。
诊断标准与关键数值
- 左室LGE预测MACE的OR 8.0(95%CI 4.3-15.0,P<.001)。
- 右室LGE预测MACE的OR 13.1(95%CI 5.2-33,P<.001)。
- FDG摄取预测MACE的OR 2.1(95%CI 1.4-3.2,P<.001)。
- 直接比较研究中LGE的OR 10.4(95%CI 3.5-30.5,P<.001),FDG摄取的OR 1.9(95%CI 0.82-4.4,P=.13)。
临床应用与阅片要点
- 在心脏结节病评估中,应重点报告左室和右室LGE的存在、范围及分布。
- FDG PET阳性摄取提示预后风险,但直接比较证据弱于LGE,报告时需结合MRI结果。
- 对于同一患者,优先关注MRI LGE的预后意义,尤其右室LGE提示更高风险。
局限性
- 直接比较MRI与PET的研究数量较少(仅5项,276例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background There is no consensus regarding the relative prognostic value of cardiac MRI and fluorodeoxyglucose (FDG) PET in cardiac sarcoidosis. Purpose To perform a systematic review and meta-analysis of the prognostic value of cardiac MRI and FDG PET for major adverse cardiac events (MACE) in cardiac sarcoidosis. Materials and Methods In this systematic review, MEDLINE, Ovid Epub, CENTRAL, Embase, Emcare, and Scopus were searched from inception until January 2022. Studies that evaluated the prognostic value of cardiac MRI or FDG PET in adults with cardiac sarcoidosis were included. The primary outcome of MACE was assessed as a composite including death, ventricular arrhythmia, and heart failure hospitalization. Summary metrics were obtained using random-effects meta-analysis. Meta-regression was used to assess covariates. Risk of bias was assessed using the Quality in Prognostic Studies, or QUIPS, tool. Results Thirty-seven studies were included (3489 patients with mean follow-up of 3.1 years ± 1.5 [SD]); 29 studies evaluated MRI (2931 patients) and 17 evaluated FDG PET (1243 patients). Five studies directly compared MRI and PET in the same patients (276 patients). Left ventricular late gadolinium enhancement (LGE) at MRI and FDG uptake at PET were both predictive of MACE (odds ratio [OR], 8.0 [95% CI: 4.3, 15.0] [P < .001] and 2.1 [95% CI: 1.4, 3.2] [P < .001], respectively). At meta-regression, results varied by modality (P = .006). LGE (OR, 10.4 [95% CI: 3.5, 30.5]; P < .001) was also predictive of MACE when restricted to studies with direct comparison, whereas FDG uptake (OR, 1.9 [95% CI: 0.82, 4.4]; P = .13) was not. Right ventricular LGE and FDG uptake were also associated with MACE (OR, 13.1 [95% CI: 5.2, 33] [P < .001] and 4.1 [95% CI: 1.9, 8.9] [P < .001], respectively). Thirty-two studies were at risk for bias. Conclusion Left and right ventricular late gadolinium enhancement at cardiac MRI and fluorodeoxyglucose uptake at PET were predictive of major adverse cardiac events in cardiac sarcoidosis. Limitations include few studies with direct comparison and risk of bias. Systematic review registration no. CRD42021214776 (PROSPERO) © RSNA, 2023 Supplemental material is available for this article.
引用
- Aitken, Davidson, Chan, et al. Prognostic Value of Cardiac MRI and FDG PET in Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. Radiology. 2023. PMID: 36809215. doi:10.1148/radiol.222483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。